The WHO Global Patient Safety Action Plan 2021-2030 is a key document that outlines the changes and aspirations that the WHO has for the next decade around protection and wellbeing of patients. The plan, produced on 3 August 2021, aims to educate various stakeholders (NHS, HCPs, pharma and patient groups) about current issues surrounding patient safety and outline their proposed solutions1. The main goal over the next 10 years is a ‘zero harm philosophy’1. This means that although it’s impossible to totally wipe out errors in patient safety, the goal is to work towards being as close to zero harm as possible. But why are we telling you about it now? Because it’s World Patient Safety Day!
read more >>
Onyx is a specialist agency with a laser focus on orphan drugs/rare diseases, regenerative medicine including gene therapy, biosimilars and innovative medical technologies where significant unmet clinical needs exist.
Building on our deep heritage in orphan drugs/rare diseases and regenerative medicines, Onyx delivers engaging made-to-measure programmes which successfully overcome the significant and very specific communications challenges such areas present.
Onyx reflects our ability to navigate complex science and our commitment to developing communications for therapies at the cutting edge of medicine using a mix of traditional channels, exciting new innovations in the digital space and avant-garde creativity.
Mantra.
Cutting-edge healthcare. Cutting-edge communications.
Recent Highlights.
Cell Therapy Manufacturing & Gene Therapy Congress in Brussels 2016
Howard Sinclair presenting at the Cell Therapy Manufacturing & Gene Therapy Congress in Brussels earlier this year, a particular honour for the Onyx team.
Vacancies.
We’re always looking for brilliant people to join our teams! Click the link to find out more about becoming part of Prime Global, view available roles, and apply.
Interesting Challenges.
Random Fact.
An estimated 350 million people worldwide have a rare disease and 30% of children with rare diseases die before their 5th birthday.* Thirty-five percent of deaths in the first year of life are caused by rare diseases.*
*Source: www.globalgenes.org
News.
-
The WHO Global Patient Safety Action Plan 2021-2030: Implications for Patient Engagement in Pharma
Prime Global 17 September, 2021The WHO Global Patient Safety Action Plan 2021-2030: Implications for Patient Engagement in Pharma -
Overcoming the challenges of gene therapy
Prime Global 15 September, 2021Overcoming the challenges of gene therapyOnce considered science fiction, a number of different gene therapy approaches are now being adopted in clinical practice to target a range of diseases. Our Prime Omics team discuss ‘overcoming the challenges of gene therapy’ in their whitepaper. Read the full piece below.
read more >> -
First Patient Engagement Day a resounding success!
Prime Global 3 September, 2021First Patient Engagement Day a resounding success!We’re delighted with the success of our first annual Patient Engagement Day, held on 1 September 2021. The day was a real opportunity for partners in the patient engagement space to join conversations, support best practices and drive new ideas and innovation that help to bridge that gap between pharma and patients.
read more >>
Get in touch.
We’re always happy to hear from you
Use the contact form or get full details for each of our offices around the world.
Contact us